Abstract
The recently completed Breast Cancer Prevention Trial found that tamoxifen can reduce the incidence of breast cancer by nearly half in women at high risk, but the benefit comes at a price of increased risk of endometrial cancer and thromboembolism. This article reviews the actions of tamoxifen and the design, findings, and implications of this study.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Breast Neoplasms / prevention & control*
-
Chemotherapy, Adjuvant
-
Drug Approval
-
Endometrial Neoplasms / chemically induced
-
Estrogen Antagonists / adverse effects
-
Estrogen Antagonists / therapeutic use*
-
Female
-
Humans
-
Middle Aged
-
Patient Selection
-
Piperidines / pharmacology
-
Piperidines / therapeutic use
-
Prospective Studies
-
Raloxifene Hydrochloride
-
Risk Assessment
-
Tamoxifen / adverse effects
-
Tamoxifen / therapeutic use*
-
United States
-
United States Food and Drug Administration / legislation & jurisprudence
Substances
-
Estrogen Antagonists
-
Piperidines
-
Tamoxifen
-
Raloxifene Hydrochloride